-

Dexcom Publishes Annual Sustainability Report

  • Report advances Dexcom’s environmental, social, and governance (ESG) transparency by providing new disclosures, including company’s first greenhouse gas emissions inventory and enhanced human capital reporting

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report, which provides updates on key environmental, social, and governance (ESG) initiatives that are aligned with Dexcom’s core values and business strategy.

“At Dexcom, we recognize and value the significant trust placed in our company not only by our global customer base, but also our employees and their families, our communities and our shareholders,” said Kevin Sayer, chairman, president and CEO of Dexcom. “We believe that by advancing the interests of our key stakeholders, we can both support the success of our business and drive greater health and economic benefits for our users and global health systems.”

Dexcom’s sustainability initiatives are integrated as foundational elements of the company’s core values and business strategy. The annual report is once again framed according to the company’s four core values: Listen, Think Big, Be Dependable, and Serve with Integrity.

Highlights from this year’s report include:

  • Enhanced reporting on environmental initiatives, including the company’s inaugural greenhouse gas emissions disclosure and Task Force on Climate-Related Financial Disclosures (TCFD) Index
  • Significant additions to human capital reporting that demonstrate the company’s ongoing commitment to diversity, equity, and inclusion, including Dexcom’s latest EEO-1 report, and additional disclosure related to the diversity of those serving in senior roles. In addition, the company has committed to work with an external consultant to conduct an adjusted pay gap analysis with respect to gender and ethnicity, with quantitative disclosure to come in the company’s 2024 Sustainability Report.
  • Updates related to the company’s multifaceted access to healthcare strategy, which has resulted in several key expansions of coverage for people with diabetes in the U.S. and international markets.

Dexcom’s annual Sustainability Report can be found on the company’s investor relations site at the following link: Dexcom Sustainability Report. All data in the report reflects fiscal year 2022, unless noted otherwise.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

More News From DexCom, Inc.

Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now available in Belgium, Germany, the Kingdom of Saudi Arabia, the Netherlands, and Spain with further EMEA country launches planned for 2026. Guided directly by H...

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM sy...

Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as...
Back to Newsroom